Pluri to take 50% stake in ZEO ScientifiX via exclusive regenerative-medicine license; raises $1M at $1.10/share

Pluri Inc.

• Pluri grants ZEO an exclusive U.S. license to manufacture and commercialize its regenerative medicine portfolio (aesthetics/skin care excluded), expandable to Latin America.
• Consideration: 41% of ZEO shares plus 50 Series D preferred shares carrying 51% of ZEO votes; cross-share swaps lift Pluri to 50% of ZEO with 4 of 7 board seats.
• Five-year ZEO warrants for 5% at $4.00/share and 2.5% at $5.50/share, plus another 5% if ZEO's 10-day VWAP reaches $5.50; closing due within 90 days of Oct 26, 2026.
• Separate Oct 27 purchase agreements: two investors buy 909,092 PLUR shares at $1.10 plus 909,092 warrants at $1.30, for $1.0M total, closing by Oct 30, 2026.
• EIB sold its ~$27.5M Pluri loan (disbursed €20M tranche at 4%, due June 1, 2026) to Chutzpah Holdings, owned by chairman Alexandre Weinstein; settlement terms not yet agreed.